PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer

Journal of Immunotherapy

Volumn 35, Issue 2, 2012, Pages 169-178

  Dulos, John ^a   Carven, Gregory J ^c   Van Boxtel, Susan J ^a   Evers, Sabine ^a   Driessen Engels, Lilian J A ^a   Hobo, Willemijn ^a   Gorecka, Monika A ^a   De Haan, Anton F J ^a   Mulders, Peter ^b   Punt, Cornelis J A ^b   Jacobs, Joannes F M ^b   Schalken, Jack A ^b   Oosterwijk, Egbert ^b   Van Eenennaam, Hans ^a   Boots, Annemieke M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PFIZER INC   (United States)

Author keywords

melanoma; PD 1; prostate cancer; Th1 Th2; Th17

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; IPILIMUMAB; PROGRAMMED DEATH 1 LIGAND 1; STAPHYLOCOCCUS ENTEROTOXIN B; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; ARTICLE; BLOOD; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPHOCYTE; MELANOMA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BLOCKING; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR IMMUNITY;

ANTIBODIES, BLOCKING; CELL SEPARATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MALE; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSTATIC NEOPLASMS; TH1 CELLS; TH17 CELLS; TH2 CELLS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84856862354     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318247a4e7     Document Type: Article

References (49)

1. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7- H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
2. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106. (Pubitemid 46160986)
3. Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev. 2011;30:125-140.
4. Cheever MA, Higano C. PROVENGE (Sipuleucel-T) in prostate cancer: The first FDA approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520-3526.
5. Culver ME, Gatesman ML, Mancl EE, et al. Ipilimumab: A novel treatment for metastatic melanoma. Ann Pharmacother. 2011;45:510-519.
6. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-548. (Pubitemid 40563179)
7. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239-245. (Pubitemid 46745373)
8. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229:114-125.
9. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. (Pubitemid 351600389)
10. Okazaki T, T Honjo. PD-1and PD-1 ligands: From discovery to clinical application. Int Immunol. 2007;19:813-824. (Pubitemid 47241890)
11. Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945-954. (Pubitemid 38924267)
12. Nishimura H, Nose M, Hiai H, et al. Development of lupuslike autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141-151. (Pubitemid 29428807)
13. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9:1477-1483. (Pubitemid 38004774)
14. Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PDL1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors. Neoplasia. 2006; 8:190-198. (Pubitemid 43671234)
15. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104:3360-3365. (Pubitemid 46364164)
16. Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer. 2006;5: 206-211. (Pubitemid 46190382)
17. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151-2157. (Pubitemid 46649885)
18. Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15:971-979.
19. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757-1766.
20. Ghebeh H, Barhoush E, Tulbah A, et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57.
21. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114:1537-1544.
22. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757-1761. (Pubitemid 46952942)
23. Wong RM, Scotland RR, Lau RL, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007; 19:1223-1234. (Pubitemid 47500645)
24. Barach YS, Lee JS, Zang X. T cell coinhibition in prostate cancer: New immune evasion pathways and emerging therapeutics. Trends Mol Med. 2010.
25. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089-1096. (Pubitemid 40216472)
26. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293-12297.
27. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2005;17:133-144. (Pubitemid 40246578)
28. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28:3167-3175.
29. Keler T, Halk E, Vitale L, et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol. 2003;171:6251-6259. (Pubitemid 37467248)
30. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-8377. (Pubitemid 36842552)
31. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-6053.
32. Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: Immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011;17:896-906.
33. Steenbakkers PG, van Meel FC, Olijve W. A new approach to the generation of human or murine antibody producing hybridomas. J Immunol Methods. 1992;152:69-77.
34. Carven G, van Eenennaam H, Dulos J. Antibodies to human programmed death receptor PD-1. 2008, Patent application: WO/2008/156712, 2008.
35. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother. 2011;60:433-442.
36. Bingham CO III, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis Rheum. 2010;62:64-74.
37. Morse MA, Hobeika A, Osada T, et al. Long term disease-free survival and T cell and antibody responses in women with highrisk Her2+ breast cancer following vaccination against Her2. J Transl Med. 2007;5:42.
38. Pages F, Galon J, eu-Nosjean MC, et al. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene. 2010;29:1093-1102.
39. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37:473-484.
40. Chen H, Liakou CI, Kamat A, et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFNgamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA. 2009;106:2729-2734.
41. Liakou CI, Kamat A, Tang DN, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA. 2008;105:14987-14992.
42. Sun J, Schiffman J, Raghunath A, et al. Concurrent decrease in IL- 10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun. 2008;8:9.
43. von EE, Chodon T, Attar N, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009;7:1-13.
44. Campbell DE, Tustin NB, Riedel E, et al. Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes. Clin Vaccine Immunol. 2009;16:1648-1653.
45. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114: 1141-1149.
46. Wang W, Lau R, Yu D, et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009;21:1065-1077.
47. Koenen HJ, Smeets RL, Vink PM, et al. Human CD25high- Foxp3pos regulatory T cells differentiate into IL-17- producing cells. Blood. 2008;112:2340-2352.
48. Salama AD, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003; 198:71-78. (Pubitemid 36870187)
49. Sakai S, Kawamura I, Okazaki T, et al. PD-1-PD-L1 pathway impairs T(h)1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Guerin. Int Immunol. 2010;22:915-925.